----item----
version: 1
id: {CD5BD27E-1253-462A-96C0-79167F6FDB50}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/AllStories/2015/01/29/Janssens Yondelis gains priority review in soft tissue sarcoma
parent: {29D5AD37-FF1E-4C35-B92F-41DC12908347}
name: Janssens Yondelis gains priority review in soft tissue sarcoma
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 333bfabb-8bb7-4b5c-9cea-ec14b8d7b088

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{DA44CA46-4196-4BEB-9C53-EC7BF60AB02C}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 63

Janssen's Yondelis gains priority review in soft tissue sarcoma
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 62

Janssens Yondelis gains priority review in soft tissue sarcoma
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1931

<p>Johnson & Johnson subsidiary Janssen Research & Development was granted a priority review by the FDA for Yondelis (trabectedin) as a treatment for patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.</p><p>The drug is a multimodal synthetically produced antitumor agent, originally derived from the sea squirt, <i>Ecteinascidia turbinate</i>.</p><p>Yondelis, which works by preventing tumor cells from multiplying, is approved in 77 countries in North America, Europe, South America and Asia as a single agent for advanced soft-tissue sarcomas.</p><p>The drug in combination with Doxil/Caelyx (doxorubicin HCl liposome injection) also is approved in 70 countries for relapsed ovarian cancer.</p><p>Janssen, which submitted its application this past November, has struggled to bring Yondelis to the US market in ovarian cancer &ndash; abandoning its plans in 2011 to seek the FDA's nod (scripintelligence.com, <a href="http://www.scripintelligence.com/policyregulation/JandJJanssen-seek-US-Yondelis-OK-in-soft-tissue-sarcoma-355246" target="_new">25 November 2014</a>, <a href="http://www.scripintelligence.com/researchdevelopment/Centocor-Ortho-abandons-pursuit-of-US-marketing-for-ovarian-cancer-drug-for-now-314908" target="_new">3 May 2011</a>).</p><p>The US application for Yondelis was based on a randomized, open-label Phase III study, known as ET743-SAR-3007, which evaluated the safety and efficacy of the drug versus dacarbazine for the treatment of patients with advanced liposarcoma and leiomyosarcoma, the most common types of STS in adults, in more than 500 patients previously treated with an anthracycline and ifosfamide, or an anthracycline followed by one additional line of chemotherapy. </p><p>Janssen said the results of the study will be presented at a future date.</p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 320

<p>Johnson & Johnson subsidiary Janssen Research & Development was granted a priority review by the FDA for Yondelis (trabectedin) as a treatment for patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy, including an anthracycline.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 62

Janssens Yondelis gains priority review in soft tissue sarcoma
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150129T080000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150129T080000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150129T080000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 10

SC00027713
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{B17EB169-D816-450D-BAF5-3AEE9B8BC441}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 63

Janssen's Yondelis gains priority review in soft tissue sarcoma
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 9

Editorial
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356438
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160127T233900Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

333bfabb-8bb7-4b5c-9cea-ec14b8d7b088
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160127T233900Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
